The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

BACKGROUND: Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimumab-induced AEs have lead to a reductio...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Voskens, Caroline J., Goldinger, Simone M., Loquai, Carmen, Robert, Caroline, Kaehler, Katharina C., Berking, Carola, Bergmann, Tanja, Bockmeyer, Clemens L., Eigentler, Thomas, Fluck, Michael, Garbe, Claus, Gutzmer, Ralf, Grabbe, Stephan, Hauschild, Axel, Hein, Rüdiger, Hundorfean, Gheorghe, Justich, Armin, Keller, Ullrich, Klein, Christina, Mateus, Christine, Mohr, Peter, Paetzold, Sylvie, Satzger, Imke, Schadendorf, Dirk, Schlaeppi, Marc, Schuler, Gerold, Schuler-Thurner, Beatrice, Trefzer, Uwe, Ulrich, Jens, Vaubel, Julia, von Moos, Roger, Weder, Patrik, Wilhelm, Tabea, Göppner, Daniela, Dummer, Reinhard, Heinzerling, Lucie M.
Format: Artigo
Jezik:Inglês
Izdano: Public Library of Science 2013
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3544906/
https://ncbi.nlm.nih.gov/pubmed/23341990
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0053745
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items